Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price ▼ | Potential |
|---|---|---|---|---|---|---|---|
| Medpace Holdings Inc | 11 | 0 | 2 | 0 | €357.60 | €419.64 | 17.348% |
| United Therapeutics | 19 | 0 | 4 | 0 | €244.10 | €287.40 | 17.739% |
| Charles River Labs Intl | 10 | 0 | 1 | 0 | €196.20 | €248.57 | 26.692% |
| Alnylam Pharmace. | 36 | 0 | 2 | 0 | €137.90 | €236.30 | 71.355% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €144.35 | €184.76 | 27.994% |
| Neurocrine Bioscience | 31 | 0 | 8 | 0 | €123.00 | €140.60 | 14.312% |
| Ultragenyx Pharmaceutical Inc. | 17 | 1 | 1 | 0 | €35.60 | €84.74 | 138.045% |
| Catalent Inc. | 1 | 0 | 0 | 0 | €49.50 | €55.00 | 11.111% |
| Arrowhead Pharmaceuticals Inc. | 14 | 2 | 2 | 0 | €22.08 | €52.03 | 135.620% |
| Halozyme Therapeutics Inc. | 15 | 0 | 3 | 0 | €39.62 | €47.17 | 19.056% |
| PTC Therapeutics Inc. | 15 | 8 | 3 | 3 | €33.20 | €41.51 | 25.038% |
| Agios Pharmaceuticals Inc. | 6 | 0 | 1 | 0 | €35.20 | €38.99 | 10.763% |
| Xencor Inc. | 10 | 1 | 1 | 0 | €20.80 | €32.58 | 56.629% |
| Exelixis Inc. | 18 | 0 | 3 | 0 | €18.72 | €26.01 | 38.960% |
| Iovance Biotherapeutics Inc. | 21 | 3 | 2 | 0 | €8.50 | €25.20 | 196.434% |
| Amicus Therapeutics Inc. | 6 | 0 | 3 | 0 | €8.55 | €17.78 | 107.944% |
| Emergent Biosolutions Inc. | 2 | 3 | 0 | 0 | €4.35 | €4.62 | 6.236% |
| Nektar Therapeutics | 3 | 1 | 0 | 0 | €1.37 | €3.70 | 170.864% |
| Novocure Ltd | 1 | 1 | 0 | 0 | €20.24 | - | - |
| Blueprint Medicines Corp | 2 | 0 | 1 | 0 | €93.82 | - | - |